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Abstract
The emergence of the influenza A(H1N1) 2009 virus prompted the development of sensitive RT-PCR detection methods. Most are real
time RT-PCRs which can provide viral quantification. In this manuscript, we describe a universal influenza A RT-PCR targeting the
matrix (M) gene, combined with an RNaseP RT-PCR. These PCRs allow the detection of all influenza A virus subtypes, including
A(H1N1)2009, together with a real-time assessment of the quality of the specimens tested. These PCR procedures were evaluated on
209 samples collected from paediatric patients. Viral loads determined through Ct values were corrected according to the RNaseP Ct
value. The mean viral load in the collected samples was estimated to be 6.84 log RNA copies/mL. For poor quality samples (RNaseP
Ct > 27), corrections resulted in +3 to +8 Ct values for the M gene RT-PCR. Corrected influenza Ct values were lower in late
samples. No correlation was established between viral loads and clinical severity or duration of disease.This study shows that real time
RT-PCR targeting the matrix gene is a reliable tool for quantification of type A influenza virus but emphasises the need for sample
quality control assessment through cellular gene quantification for reliable estimation of the viral load. This method would be useful for
disease management when repeated specimens are collected from an infected individual.
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Introduction
The new variant A(H1N1) influenza virus was originally
detected in April 2009 in Mexico and the USA. Subsequently,
it disseminated worldwide. In France, this virus was first
detected in May 2009 and the first epidemic was reported in
October, with the proportion of severe cases and deaths
increasing rapidly (http://www.invs.sante.fr/surveillance/
grippe_dossier/index_H1N1.htm).
The RNA genome of A(H1N1)2009 virus comprises a
specific combination of gene segments that had never previ-
ously been detected [1–3]. Moreover, specific clinical
features have been reported for infections associated with
the A(H1N1)2009 virus. Most hospitalized patients are under
the age of 18 and very few are over 65 years [4]. Pneumonia
is detected in 40% of cases [4]. Between 40% and 70% of
patients with severe symptoms have an underlying medical
history [2,4].
Since May 2009, the two French National Influenza Cen-
tres (NICs) have worked together to develop rapid and sen-
sitive methods to detect the A(H1N1)2009 virus. The
strategy chosen included two real-time RT-PCRs: one target-
ing the M gene (M RT-PCR) for sensitive detection of all
subtypes of type-A influenza virus and the second, targeting
the HA gene, for specific detection of A(H1N1)2009 virus.
The M RT-PCR described here was actually developed for
influenza A virus quantification before the emergence of the
A(H1N1)2009 virus. This PCR strategy was supported by a
ribonuclease P (RNase P) RT-PCR for assessment of the
quality of the samples. In addition to real time evaluation of
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the quality of specimens, we also looked for evidence of a
relationship between Ct value (viral load) and disease sever-
ity during the A(H1N1)2009 pandemic.
Materials and Methods
Patients
Overall, 209 patients positive for A(H1N1)2009 were
included in the study between the 1st of October 2009 and
the 4th of November 2009. Clinical data were collected retro-
spectively. The mean age of the patients was 5.9 years (±3.8);
12.5% of the patients were below 1 year of age. The M:F sex
ratio was 1.06. There was no health risk factor in 63.5% of the
patients; reported health risk factors were asthma (24.5%),
chronic cardiac disease (4.8%), prematurity (3.8%) and other
(3.4%). The mean delay between onset of clinical symptoms
and consultation was 2.07 days (±2 days). The most fre-
quently reported symptoms were cough (87.9%), fever
(86.2%), rhinitis (36.2%) and myalgia (22.2%). Nine per cent of
the patients were hospitalized, only one of whom required
admission to the intensive care unit. Neuraminidase inhibitors
were prescribed in 41.6% of the cases, with oseltamivir or
zanamivir in 92.6% and 6.2% of the treated cases, respectively.
Samples
Nasal swabs were sent to the laboratory in <12 h after sam-
pling. Upon arrival, they were placed in 3 mL of transport
medium for viral culture; 200 lL of this medium was used
for RNA purification on NucliSens easyMAG instrument
(bioMe´rieux). After extraction, RNA was eluted in 70 lL
and stored at +4C until RT-PCRs were performed the same
day. Longer storage was carried out at )80C.
To determine the specificity of the RT-PCRs, 16 samples
from patients positive for different respiratory viruses were
tested in M RT-PCR and H1 RT-PCR (developed by NIC,
North of France, Institut Pasteur, Paris). These samples were
known to be positive for seasonal influenza A(H1N1),
A(H3N2), B viruses, respiratory syncytial virus A or B, boca-
virus, parainfluenza 1–3, metapneumovirus, rhinovirus,
enterovirus, adenovirus, cytomegalovirus, herpes simplex
virus or varicella-zoster virus.
To validate the wide spectrum of influenza A subtypes
detected by M RT-PCR, we tested 18 avian, swine and
human A influenza viruses including A/Vietnam/1194/2004
(H5N1), A/Turkey/13/2006 (H5N1), A/Finch/England/2051/
2002 (H5N2) and A/Swine/England/117316/86 (H1N1).
A calibrated synthetic RNA transcript was kindly provided
by V. Enouf and S. van der Werf (NIC North of France,
Institut Pasteur, Paris) and used for the assessment of the M
RT-PCR. This transcript is the negative strand of the Open
Reading Frame of the M gene (from the ATG to nucleotide
982). The transcript was diluted in distilled water to obtain a
solution at a concentration of 109 copies/lL and stored at
)80C. Two dilutions were used in each assay: 104 copies/
5 lL, corresponding to a Ct value of 30 and 105 copies/5 lL,
corresponding to a Ct value of 26.
Influenza real time RT-PCR
The primers and probe targeting the haemagglutinin gene
and designed for the specific detection of A(H1N1)2009 are
available upon request (grippe@pasteur.fr). The primers tar-
geting the matrix gene and designed for universal detection
of influenza A viruses were previously described for a classi-
cal RT-PCR [5] and the probe was designed on Primer
Express version 3 software (Applied Biosystem, Foster City,
CA, USA) (Table 1). Specificity of oligonucleotides was
assessed by performing a local alignment search (blastn;
http://blast.ncbi.nlm.nih.gov./Blast.cgi).
Reactions were performed in duplicate in 25 lL final vol-
ume reaction containing 5 lL of purified nucleic acid tem-
plate, 12.5 lL of 2· reaction mix (3 mM Mg2+), 2 lL of each
10 lM primers (final concentration at 800 nM) and 1 lL of
5 lM probe (final concentration at 200 nM). Finally 0.5 lL of
Rox reference dye (10-fold pre-diluted) was added and
0.5 lL of enzyme mix (Superscript III Platinum One-Step
Quantitative RT-PCR System, Invitrogen, Carlsbad, CA,
USA). Thermocycling reaction conditions were: reverse tran-
scription at 50C for 15 min; Taq activation and denaturation
at 95C for 2 min, followed by 50 PCR amplification cycles
including one step at 95C for 15 s and one step at 60C for
40 s (hybridization-elongation). RT-PCR assays were
performed on an ABI 7500 (Applied Biosystem).
Efficiency, reproducibility, repeatability, specificity and cal-
culation of the limit of detection were determined according
to guidelines proposed by Bustin et al. [6] and Rabenau et al.
[7]. To validate the M RT-PCR as a quantitative RT-PCR
for the determination of influenza A viral load, we prepared
TABLE 1. M gene RT-PCR primers
and probeSequences
Viral
target
PCR
product size
M/Fw CTTCTAACCGAGGTCGAAACGTA
M/Rv GGTGACAGGATTGGTCTTGTCTTTA Viral M gene 202 bp
M probe+ TCAGGCCCCCTCAAAGCCGAG [5¢]Fam [3¢]BHQ-1
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10-fold dilution series of the calibrated synthetic RNA tran-
script. Six dilutions (10–106 copies/5 lL of synthetic RNA
transcript) were tested in duplicate within the same sample
run and compared. Standard curves were produced with
these six standard points.
RNaseP real time RT-PCR and Influenza Ct correction
The ribonuclease P (RNaseP) RT-PCR was an in-house multi-
plex method allowing the detection of rhinovirus and RNa-
seP gene, which is a human cellular gene. Primers and probe
for RNaseP detection are available at the CDC (cdcinfo@
cdc.gov). The detection of this gene was used both as an
internal control and to check for the presence of human
nucleic acids and indicates the presence of a sufficient
amount of cells in the sample. RNaseP Ct values were all
determined using the same fluorescence threshold (0.02
dRn). They were used to correct influenza A viral load for
each sample, calculating a Ct value modified according to the
ratio of sample RNaseP and mean RNaseP Ct values ([sam-
ple influenza A Ct value (M RT-PCR) x sample RNaseP Ct
value/mean RNaseP Ct value]).
Statistical analysis
Student’s t-test and Pearson chi square-test were used to
assess intergroup differences. Statistical analyses were per-
formed on EpiInfo software (V 3.5.1 CDC). A test was con-
sidered as significant when p-value was below 0.05.
Results
Influenza A M gene RT-PCR assay performance
Data on M RT-PCR performance were calculated from 28
assays (Table 2). The M RT-PCR quantification using 10-fold
dilution series of the calibrated synthetic RNA transcript
showed a strong correlation between viral load of the sam-
ple and Ct value (mean R2 = 0.99 ± 0.01). PCR reaction effi-
ciency was between 86.6% and 98.6%. The detection limit
was between 101 and 102 copies of synthetic RNA tran-
script. The lowest concentrations of the RNA transcript
(101, 102 and 103 copies/5 lL) were individually tested 20
times. The probability of detecting 103 and 102 copies was
100%, compared with 35% for a concentration of ten copies.
According to the RNA purification protocol used, a limit of
detection between 10 and 102 copies/5 lL ensures detection
of 700–7000 copies/mL of initial sample (Table 3).
The repeatability of the M RT-PCR, tested on six positive
samples with a mean Ct value of 28.18 and three low posi-
tives samples (mean Ct value = 37.11), showed a standard
deviation of Ct values of 0.07 ± 0.04 for positive samples
and 0.79 ± 0.19 for low positive samples (Table 4).
For reproducibility, two positive samples with a mean Ct
value of 29.92 and one low positive sample (Ct
value = 36.43) tested three times within three different
assays performed on a 3-days period, showed a standard
deviation of Ct values at fluorescence threshold 0.2 dRn of
0.16 ± 0.02 for positive samples and 0.39 for the low posi-
tive sample (Table 4).
Ct normalisation according to the quality of the samples
The mean Ct value for influenza A was 26.4 ± 5.2 [16.4–
39.9]. This is the same Ct value as the 105 copies/5 lL RNA
transcript standard point, corresponding approximately to a
viral load of 6.84 log/mL of sample in viral transport medium.
For RNaseP, the mean Ct value was 24.7 ± 1.9 [19.9–31.8].
Among the specimens tested, 52% had RNaseP Ct values
below 25%, 21% between 25 and 27, and 9.6% over 27. This
last group with high RNaseP Ct values represents swabs
containing very few cells, as confirmed by immunofluores-
cence assays (data not shown). These correspond to virolog-
ically poor quality samples. According to the detection limit
of our technique, 20% of samples with influenza A Ct values
>35 had RNaseP Ct values >27, corresponding to poor qual-
ity specimens.
TABLE 2. M gene RT-PCR performance
M gene RT-PCR
Number of replicates 28
Slope (mean ± SD) )3.359 ± 0.13
Coefficient of determination (R2) 0.99 ± 0.01
Efficiency (%) 91.86 ± 3.44
TABLE 3. M gene RT-PCR detection limit
No. of positive tests
out of 20 tests (%) Mean Ct ± SD
1000 copies/5 lL 20 (100) 33.35 ± 0.40
100 copies/5 lL 20 (100) 36.70 ± 1.36
10 copies/5 lL 7 (35) 39.30 ± 1.09
TABLE 4. M gene RT-PCR repeatability and reproducibility
No. of samples
tested Mean Ct SD (mean ± SD)
Repeatability
Positive 6 28.18 0.07 ± 0.04
Low positive 3 37.11 0.79 ± 0.19
Reproducibility
Positive 3 29.92 0.16 ± 0.02
Low positive 1 36.43 0.39
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Influenza A Ct values were normalized according to RNa-
seP Ct values in order to adjust the quantity of virus
detected for the quality of the samples. This correction
resulted in an increase of influenza Ct up to 6.5 for low
quality samples (with high RNaseP Ct values) or a decrease
of influenza Ct up to 8.4 for high quality samples (with low
RNaseP Ct values). After correction, the influenza A mean
Ct value was 26.3 ± 3 [16.7–43.4] and 31% of the samples
had corrected influenza A Ct values below 23, 25% between
23 and 29, and 44% over 29, this last group corresponding
to low viral loads.
Ct value according to sampling time
Corrected influenza A Ct values were analysed according to
the period between the onset of the disease and sampling
time. The mean value was 25.7 for a period <1 day, 27.1
between 2 and 3 days, and 28.7 over 3 days (differences
were significant, p = 0.024). Most of the samples in this
study were taken no more than 3 days after disease onset
(Table 5); 26% were taken after this. Among this last group
of late samples, 39% had high corrected influenza A Ct val-
ues >29. Nevertheless 46% of samples taken <1 day after
disease onset also presented high influenza A Ct values,
probably because of poor quality samples.
Ct value according to clinical severity
Corrected influenza A Ct values were analysed according to
specific clinical features of influenza disease and to patient
medical history (Table 6). Viral load, as estimated by cor-
rected Ct values, never appeared to correlate with clinical
history or specific clinical symptoms. However, we observed
a trend for higher viral load in patients presenting with
marked signs of upper respiratory infections, not related to
severe cases.
Discussion
Here we report a real time RT-PCR protocol developed
2 years ago for research applications. This one-step RT-PCR
targeting the matrix gene is able to detect all subtypes of
influenza A viruses including A(H1N1)2009. This M RT-PCR is
rapid (<1.5 h), specific and sensitive, with a limit of detection
between 10 and 100 copies/reaction. Viral loads of 700 copies/
mL of sample were frequently detected; this value is in accor-
dance with other reports of detection limits between 570 and
900 copies/mL [8,9]. For the detection of A(H1N1)2009, this
M RT-PCR was associated with a specific RT-PCR targeting
the haemagglutinin gene. This strategy is pertinent in the
context of a pandemic as the new virus may drift, mainly due
to mutation in haemagglutinin and/or neuraminidase genes,
but variants will still be detected by this universal M RT-PCR.
The relationship between viral quantification and clinical
severity in viral respiratory diseases is an important issue. It
has previously been reported for seasonal influenza that
patients hospitalized with severe diseases have more active
and prolonged viral replication [10]. Recent reports
described a median of A(H1N1)2009 viral load of 4.6 log
RNA copies/mL in respiratory samples [9]. The value
reported here is higher (6.84 log RNA copies/mL), probably
because it was measured in a paediatric population compris-
ing mostly (91) non-hospitalized children presenting with
mild influenza symptoms. However, a recent study reported
even higher viral loads, reaching 8.26 log/mL [8]. In addition
to developing a reliable quantification tool such as the one
described here, the main difficulty in viral load measurement
is that the usual nasal swab sample is often of poor quality.
In this study, 10% of the samples received were associated
with high RNaseP Ct value (>27). This reflects poor quality
specimens with very few cells, as confirmed by immunofluo-
rescence assays. The impact of the quality of the sample on
influenza quantification may be very high as, for poor quality
samples (RNaseP Ct > 27), the correction of influenza Ct is
over 3 Ct (1 log) and may be up to 6–8 Ct (2–3 log). In
order to attempt to establish influenza viral load for disease
management or clinical severity correlation, it is very impor-
tant to assess the quality of the sample and to correct viral
load accordingly.
TABLE 5. Corrected influenza A Ct values according to
sampling time post symptom onset
<23 23–29 >29
Number
of samples
Period below 1 day 34 (34%) 20 (20%) 45 (46%) 99
Period from 2 to 3 days 15 (26%) 27 (46%) 16 (28%) 58
Period over 3 days 4 (15%) 12 (46%) 10 (39%) 26
TABLE 6. Corrected influenza A mean Ct values according
to clinical features
Clinical features
Mean Ct
value with
this feature
Mean Ct
value without
this feature p-Value
Cardiac or respiratory
disease (including asthma)
medical history
26.5 26.0 0.52
Asthma 25.9 26.5 0.49
Myalgia 25.9 26.6 0.46
Digestive symptoms 26.6 26.3 0.76
Upper respiratory infection 26.9 26.1 0.27
Lower respiratory infection 25.2 25.4 0.46
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In addition to poor quality samples, we showed that sam-
ple delay resulted in an increase of Ct values. This has also
been recently reported by To et al. [8] who described a
1 log decrease for samples taken 3 days after disease onset.
Finally, even though our study failed to correlate any spe-
cific clinical features with influenza viral load, probably
because the cases were mostly non-hospitalized children
with mild symptoms, we consider that this normalized tech-
nique is of interest for disease management. Our results pro-
vide a standard reference viral load method that can be used
in similar studies analysing severe cases.
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